CTMX - CytomX Therapeutics Inc
IEX Last Trade
1.18
0.030 2.542%
Share volume: 208,674
Last Updated: Fri 30 Aug 2024 09:59:52 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.15
0.03
2.61%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-08 | 2023-03-27 | 2023-05-09 | 2023-08-08 | 2023-11-07 | 2024-03-11 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 260.086 M | 226.492 M | 260.891 M | 234.630 M | 209.185 M | 221.167 M | 201.792 M | 184.687 M | |
| Current Assets | 232.770 M | 200.280 M | 237.102 M | 212.277 M | 187.801 M | 201.204 M | 182.936 M | 167.247 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.591 M | 4.278 M | 7.466 M | 6.685 M | 5.040 M | 4.675 M | 4.995 M | 3.786 M | |
| Short Term Investments | 3.591 M | 4.278 M | 7.466 M | 6.685 M | 5.040 M | 4.675 M | 4.995 M | 3.786 M | |
| Total Receivables | 1.014 M | 1.712 M | 35.986 M | 1.090 M | 1.903 M | 2.419 M | 3.432 M | 13.177 M | |
| Current Cash | 228.165 M | 194.290 M | 193.650 M | 204.502 M | 180.858 M | 194.110 M | 174.509 M | 150.284 M | |
| Total Non-current Assets | 27.316 M | 26.212 M | 23.789 M | 22.353 M | 21.384 M | 19.963 M | 18.856 M | 17.440 M | |
| Property Plant Equipment | 5.915 M | 5.710 M | 5.072 M | 4.573 M | 4.499 M | 4.060 M | 3.958 M | 3.567 M | |
| Other Assets | 895.000 K | 895.000 K | 27.000 K | 27.000 K | 91.000 K | 87.000 K | 83.000 K | 80.000 K | |
| Intangible Assets | 948.000 K | 911.000 K | 875.000 K | 839.000 K | 802.000 K | 766.000 K | 729.000 K | 693.000 K | |
| Goodwill | 949.000 K | 949.000 K | 949.000 K | 949.000 K | 949.000 K | 949.000 K | 949.000 K | 949.000 K | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 260.086 M | 226.492 M | 260.891 M | 234.630 M | 209.185 M | 221.167 M | 201.792 M | 184.687 M | |
| Total liabilities | 211.378 M | 198.018 M | 346.642 M | 321.267 M | 294.212 M | 272.405 M | 249.239 M | 216.367 M | |
| Total current liabilities | 99.439 M | 97.841 M | 152.608 M | 151.262 M | 141.377 M | 146.790 M | 155.913 M | 144.536 M | |
| Accounts Payable | 1.920 M | 5.176 M | 2.809 M | 2.203 M | 1.029 M | 1.705 M | 1.458 M | 1.964 M | |
| Other liabilities | 95.863 M | 85.122 M | 180.059 M | 157.133 M | 141.089 M | 115.018 M | 83.941 M | 63.683 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 95.863 M | 85.122 M | 180.059 M | 157.133 M | 141.089 M | 115.018 M | 83.941 M | 63.683 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 48.708 M | 28.474 M | -85.751 M | -86.637 M | -85.027 M | -51.238 M | -47.447 M | -31.680 M | |
| Common stock | 65.543 M | 65.912 M | 66.111 M | 66.249 M | 66.536 M | 80.732 M | 81.716 M | 82.029 M | |
| Retained earnings | -581.793 M | -605.089 M | -722.879 M | -726.190 M | -727.277 M | -724.285 M | -723.448 M | -709.657 M |